Bortezomib is an effective agent for MDS/MPD syndrome with 5q- anomaly and thrombocytosis

Leukemia Research

Volumn 31, Issue 4, 2007, Pages 559-562

  Terpos, Evangelos ^a   Verrou, Evgenia ^b   Banti, Anastasia ^b   Kaloutsi, Vassiliki ^c   Lazaridou, Anna ^b   Zervas, Kostas ^b  

^a 251 GENERAL AIR FORCE HOSPITAL   (Greece)

^b THEAGENIO CANCER HOSPITAL   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

5q syndrome; Bortezomib; Interleukin 4; Interleukin 6; Myelodysplastic syndromes; Thrombocytosis

Indexed keywords

BORTEZOMIB; HEMOGLOBIN; HYDROXYUREA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 4; INTERLEUKIN 6; PROTEASOME INHIBITOR; RECOMBINANT ERYTHROPOIETIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BONE MARROW; CASE REPORT; CHROMOSOME 5Q; CYTOKINE PRODUCTION; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; HUMAN; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NERVE ROOT COMPRESSION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SENSORY NEUROPATHY; THROMBOCYTE COUNT; THROMBOCYTOSIS; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CHROMOSOMES, HUMAN, PAIR 5; FEMALE; HUMANS; INTERLEUKIN-4; INTERLEUKIN-6; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS; PLATELET COUNT; PYRAZINES; THROMBOCYTOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33846665846     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.05.018     Document Type: Article

References (21)

1. Van den Berghe H., and Michaux L. 5q-, twenty-five years later: a synopsis. Cancer Genet Cytogenet 94 (1997) 1-7
2. Ustundag, Haznedaroglu I.C., Ozcebe O., Dundar S., and Kirazli S. Possible cytokine mechanism of increased megakaryocytic proliferation in 5q- syndrome. Am J Hematol 52 (1996) 124 [letter]
3. Boultwood J., Lewis S., and Waincoat J.S. The 5q- syndrome. Blood 84 (1994) 3253-3260
4. Sonoda Y., Kuzuyama Y., Tanaka S., Yokota S., Maekawa T., Clark S.C., et al. Human interleukin-4 inhibits proliferation of megakaryocyte progenitor cells in culture. Blood 81 (1993) 624-630
5. Kaser A., Brandacher G., Steurer W., Kaser S., Offner F.A., Zoller H., et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood 98 (2001) 2720-2725
6. Sulkowski S., Terlikowski S., and Sulkowska M. Occlusion of pulmonary vessels by megakaryocytes after treatment with tumour necrosis factor-alpha (TNF-alpha). J Comp Pathol 120 (1999) 235-245
7. Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., Facon T., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352 (2005) 2487-2498
8. Lonial S., Waller E.K., Richardson P.G., Jagannath S., Orlowski R.Z., Giver C.R., et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 106 (2005) 3777-3784
9. Shetty V., Verspoor F., Nguyen H., Gallegos A., Mundle S., Chaudhry N., et al. Effect of proteasome inhibition by bortezomib on tumor necrosis factor-alpha (TNF-α) and apoptosis in patients with myelodysplastic syndromes (MDS). Blood 106 Suppl. 1 (2003) 1534 [abstract]
10. Nosslinger T., Reisner R., Koller E., Gruner H., Tuchler H., Nowotny H., et al. Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. Blood 98 (2001) 2935-2941
11. Cheson B.D., Bennett J.M., Kantarjian H., Pinto A., Schiffer C.A., Nimer S.D., et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96 (2000) 3671-3674
12. Cabello A.I., Collado R., Ruiz M.A., Martinez J., Navarro I., Ferrer R., et al. A retrospective analysis of myelodysplastic syndromes with thrombocytosis: reclassification of the cases by WHO proposals. Leuk Res 29 (2005) 365-370
13. Reis M.D., Sher G.D., Lakhani A., Dubé I.D., Senn J.S., and Pinkerton P.H. Deletion of the long arm of chromosome 5 in essential thrombocythemia. Cancer Genet Cytogenet 61 (1992) 93-95
14. Koike T., Uesugi Y., Toba K., Narita M., Fuse I., Takahashi M., et al. 5q- syndrome presenting as essential thrombocythemia: myelodysplastic syndrome or chronic myeloproliferative disorders?. Leukemia 9 (1995) 517-518
15. Takahashi H., Furukawa T., Hashimoto S., Kanazawa N., Satoh N., Suzuki N., et al. 5q- syndrome presenting chronic myeloproliferative disorders-like manifestation: a case report. Am J Hematol 64 (2000) 120-123
16. Richardson P.G., Mitsiades C., Hideshima T., and Anderson K.C. Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med 57 (2006) 33-47
17. Dubois D., Dhawan R., van de Velde H., Esseltine D., Gupta S., Viala M., et al. Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma. J Clin Oncol 24 (2006) 976-982
18. Strauss S.J., Maharaj L., Hoare S., Johnson P.W., Radford J.A., Vinnecombe S., et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 24 (2006) 2105-2112
19. Cortes J., Thomas D., Koller C., Giles F., Estey E., Faderl S., et al. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res 10 (2004) 3371-3376
20. Braun T., Carvalho G., Coquelle A., Vozenin M.C., Lepelley P., Hirsch F., et al. NF-kappa B constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood 107 (2006) 1156-1165
21. Hsu H.C., Lee Y.M., Tsai W.H., Jiang M.L., Ho C.H., Ho C.K., et al. Circulating levels of thrombopoietic and inflammatory cytokines in patients with acute myeloblastic leukemia and myelodysplastic syndrome. Oncology 63 (2002) 64-69